Johnson & Johnson (JNJ) said it doesn’t intend to make an offer for Horizon Therapeutics (HZNP), days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company, Bloomberg’s Susanne Barton reports. Janssen Global Services, J&J’s pharmaceutical division, didn’t provide a reason why it isn’t planning on proceeding with an offer, the author notes. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Needham healthcare analyst to hold an analyst/industry conference call
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
- Johnson & Johnson names CEO Joaquin Duato as Chairman of the Board